6,6'-ジヒドロキシ-3,3'-ジアルセン-1,2-ジイルジアニリニウムジクロリド

6,6'-ジヒドロキシ-3,3'-ジアルセン-1,2-ジイルジアニリニウムジクロリド 化学特性,用途語,生産方法

• 解説

  1910年に秦佐八郎とP.エールリヒらが開発した梅毒治療薬で，化学療法剤の第1号。有機ヒ素化合物で，化学名は3,3′‐ジアミノ‐4,4′‐ジヒドロオキシアルセノベンゼンの塩酸塩。秦らは多数の有機ヒ素化合物を合成し，それら一つ一つの実験梅毒に対する効果を調べたが，606番目のものが最も効果が高く，かつ毒性が弱いことを発見した。製造番号から，この薬剤は606号と呼ばれ，ドイツのヘキスト社からサルバルサンの名で市販された。
  株式会社平凡社 世界大百科事典 第２版について　情報

• 応用例（製薬）

  Salvarsan was a synthetic arsenic-based drug discovered in 1909 by Ehrlich and his team. In 1910, Ehrlich introduced Salvarsan (3-amino-4-hydroxyphenylarsenic), also known as arsphenamine or compound 606, to the market as a cure for syphilis caused by the bacterium Treponema pallidum.
  Eventually, compound 606 was synthesised and introduced as an agent against syphilis. The compound was later marketed as Salvarsan, receiving its name from the Latin word salvare , which means to preserve, to heal. In 1909 and 1910, the first human tests on patients with syphilis and relapsing fever were extremely successful, and Salvarsan was marketed from 1910. For the first time, an infectious and fatal disease in humans could be treated with a man-made molecule, and Salvarsan brought Ehrlich world-wide fame. Generally, the use of arsenic-based drugs has ceased, especially as a result of the development of Penicillin. Nevertheless, Melarsoprol and an arsenic-based drug closely related to Atoxyl are licensed to treat sleeping sickness.

6,6'-ジヒドロキシ-3,3'-ジアルセン-1,2-ジイルジアニリニウムジクロリド 生産企業

Global(4)Suppliers